Changes to the National Immunisation Program (NIP) will soon come into effect.
From 1 July 2023, hexavalent vaccine Vaxelis® will be added to the NIP.
Vaxelis® is used in primary vaccination series against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b (DTPa-hepB-IPV-Hib) for children at 2, 4 and 6 months of age.
Vaxelis® is also suitable and funded for use in children less than 10 years of age who have not previously received DTPa-hepB-IPV-Hib vaccination (catch-up vaccination).
Vaxelis® is being made available as an alternative NIP-funded vaccine to Infanrix® hexa, and not as a replacement vaccine. There is no preferential recommendation between the use of these two products.
Refer to the Australian Immunisation Handbook for advice.
From 1 November 2023, Shingrix® vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia will replace Zostavax® vaccine on the NIP, pending final regulatory approvals.
The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended Shingrix® vaccine as a two-dose primary course for the following eligible cohorts:
- all adults aged 70 years (only)
- First Nations Australian adults aged 50 years and older
- immunocompromised people aged 18 years and older with conditions at ‘high risk’ of herpes zoster infection.
These program changes are being implemented following recommendations from the PBAC and the Australian Technical Advisory Group on Immunisation and other clinical experts. Get the latest NIP updates by subscribing here.